Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a)
Age and Ageing · 2025
DOI: 10.1093/ageing/afaf295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, 2025. Verfasst von Xiaohui Bian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: Lipoprotein(a), Inflammation, Atherosclerosis, C-Reactive Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Inflammation and hyperlipidaemia contribute with similar magnitude to the risk of future atherothrombotic events. However, the relative importance of high-sensitivity CRP (hsCRP) and lipoprotein(a) (Lp[a]) as determinants of risk of major adverse cardiovascular events (MACE) are not well defined among patients aged 75 years or older with established atherosclerotic cardiovascular disease (ASCVD).
Methods
The present study prospectively enrolled 2,333 patients aged 75 years or older diagnosed with ASCVD with measurement of hsCRP and Lp(a) at Fuwai Hospital. The primary endpoint was MACE, defined as a composite of all-cause death, myocardial infarction (MI), stroke or ischaemia-driven coronary revascularisation.
Results
The median follow-up time was 3.0 years (interquartile range [IQR]: 2.5–3.2 years). hsCRP was significantly associated with an increased risk of MACE (adjusted hazard ratio [aHR]: 1.05, 95% confidence interval [CI]: 1.03–1.08 per 1 mg/l increment, P < 0.001; highest versus lowest quartile: aHR: 1.70 [1.22–2.38]), whereas there was no significant association between Lp(a) and MACE risk (aHR: 1.02 [0.98–1.06] per 10 mg/dl increment, P = 0.341; highest versus lowest quartile: aHR: 1.06 [0.77–1.47]). Risks of MACE were significantly higher in participants with hsCRP ≥2 mg/l than in those with hsCRP <2 mg/l, irrespective of Lp(a) strata (aHR: 1.41 [1.12–1.79]; P = 0.004). Concomitant elevation of hsCRP (≥2 mg/l) and Lp(a) (≥30 mg/dl) was associated with the greatest risk of MACE (aHR, 1.54 [1.13–2.12]; P = 0.007).
Conclusions
Inflammation assessed by hsCRP predicted risk of future cardiovascular events more strongly than Lp(a) in patients aged 75 years or older with established ASCVD. These results provided real-world evidence on older patients potentially benefit by targeted anti-inflammatory strategies for secondary ASCVD prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Xicheng District, Beijing 100…
- Coronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Xicheng District, Beijing 10003…
- State Key Laboratory of Cardiovascular Disease, Beijing 100037, China.
- National Clinical Research Center for Cardiovascular Diseases, Beijing 100037, China.
Zitieren
APA
Bian, X., Wang, H. Y., Guo, Y., Gao, Y., An, T., Dong, Q., Gao, G., Feng, L., Song, W., Yin, D., & Dou, K. (2025). Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). Age and Ageing. https://doi.org/10.1093/ageing/afaf295
Vancouver
Bian X, Wang HY, Guo Y, Gao Y, An T, Dong Q, et al. Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). Age and Ageing. 2025. doi:10.1093/ageing/afaf295
BibTeX
@article{Bian2025,
author = {Bian, Xiaohui and Wang, Hao-Yu and Guo, Yuanlin and Gao, Ying and An, Tao and Dong, Qiuting and Gao, Guofeng and Feng, Lei and Song, Weihua and Yin, Dong and Dou, Kefei},
title = {Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a)},
journal = {Age and Ageing},
year = {2025},
doi = {10.1093/ageing/afaf295}
}
EUVIMED